MIRADOR360
Live / Applied — First extension granted (statement of use) (as of 24 Sept 2025)
What this means for you
Not registered yet, but its 04 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98432118
- Mark type
- Stylized text
- Filed
- 04 Mar 2024
- Published for opposition
- 25 Feb 2025
- Attorney of record
- Brent D. Sokol
Goods and services
- Class 042 — Scientific and technological services: Scientific research services in the nature of collecting and analyzing patient data and genetic information for pharmaceutical drug development and diagnostics development including companion diagnostics development and complementary diagnostics development; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating therapeutic targets for pharmaceutical development as well as for predicting, measuring or evaluating the performance of therapeutic molecules directed at therapeutic targets; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for diagnostics including companion diagnostics development and complementary diagnostics development as well as for predicting, measuring or evaluating the performance of the diagnostics; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for selecting patients for inclusion in clinical treatment including clinical trials as well as for predicting, measuring or evaluating the performance of the patient selecting criteria; Scientific research services in the nature of collecting patient data and genetic information and analysis of such data for identifying and recruiting patients for participation in clinical trials for pharmaceutical drug development, matching patients with clinical trials and for measuring and monitoring the performance of clinical trials for pharmaceutical drug development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating therapeutic targets and therapeutic molecules in the field of pharmaceutical development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating biomarkers and other patient-selecting or patient-identifying criteria in the field of diagnostic development including companion diagnostics development and complementary diagnostics development
Owner
- Mirador Therapeutics, Inc., San Diego, CA, US
- Mirador Therapeutics, Inc., San Diego, CA, US
Prosecution history
- 25 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Sept 2025 — SOU EXTENSION 1 GRANTED
- 24 Sept 2025 — SOU EXTENSION 1 FILED
- 24 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 22 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Feb 2025 — PUBLISHED FOR OPPOSITION
- 19 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 03 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 09 Jan 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 09 Jan 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 09 Jan 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 10 Oct 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Oct 2024 — NON-FINAL ACTION E-MAILED
- 10 Oct 2024 — NON-FINAL ACTION WRITTEN